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This study was performed to determine the activity of adding continuous infusion (CI) of 5-fluorouracil (5-FU) to gemcitabine (GEM)
vs GEM alone in advanced pancreatic cancer (APC). In all, 94 chemo-naı ¨ve patients with APC were randomised to receive GEM
alone (arm A: 1000mgm
 2 per week for 7 weeks followed by a 2 week rest period, then weekly for 3 consecutive weeks out of
every 4 weeks) or in combination with CI 5-FU (arm B: CI 5-FU 200mgm
 2day
 1 for 6 weeks followed by a 2 week rest period,
then for 3 weeks every 4 weeks). Overall response rate (RR) was the primary end point and criteria for decision were planned
according to the Simon’s optimal two-stage design. The overall RR was 8% (arm A) and 11% (arm B) (95% confidence interval: 0.5–
16% and 2–22%), respectively, and stable disease was 29 and 28%. The median duration of RR was 34 weeks (range 25–101 weeks)
for GEM and 26 weeks (range 16–46 weeks) for the combination. The median progression-free survival (PFS) was 14 weeks (range
2–65 weeks) and 18 weeks (range 4–51 weeks), respectively. The median overall survival (OS) was 31 weeks (range 1–101 weeks)
and 30 weeks (1–101 weeks). Toxicity was mild in both arms. This study does not show promising activity in terms of RR, PFS and
OS for the double combination arm in APC.
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Pancreatic cancer is the fifth most common cancer worldwide.
Unfortunately, most patients have locally advanced or metastatic
pancreatic cancer and usually are poorly responsive to chemother-
apy (Greenlee et al, 2001). Randomised studies have revealed a
significant better overall survival (OS) with chemotherapy against
best supportive care (BSC) (Weinerman and MacCormick, 1994;
Glimelius et al, 1996). Although the increase in median survival
was modest: 4 and 6 months for the treatment group as compared
with 3 and 2.5 months for BSC, respectively, various schedules and
different regimens have been evaluated with no proven benefit
over single-agent 5-fluorouracil (5-FU) (Cullinan et al, 1985;
Cullinan et al, 1990). In advanced pancreatic cancer (APC),
continuous infusion (CI) of 5-FU is superior to 5-FU bolus in
terms of response rate (RR) and toxicity (Hansen et al, 1988;
Hidalgo et al, 1999).
Gemcitabine (GEM), a deoxycitidine analogue, has demon-
strated activity in APC in terms of clinical benefit and survival
(Rothenberg et al, 1996). A phase III trial compared GEM vs 5-FU
alone, the GEM arm showed a statistically longer survival and
better clinical benefit (Burris et al, 1997). Phase I and II trials of
GEM plus 5-FU bolus reported interesting results in terms of
clinical benefit (38–66%). Recently, Eastern Cooperative Oncology
Group (ECOG) randomised patients with APC to 5-FU plus GEM
vs GEM alone. The OS was better, but not significant in the
combination arm (6.7 vs 5.4 months; P¼0.09) and grade 3 and 4
leukopenia, thrombocytopenia and diarrhoea was higher in the
combination arm. Several combination regimens with 5-FU,
cisplatin, capecitabine, irinotecan, oxaliplatin, premetrexed and
docetaxel were developed without a sure advantage (Cartwright
et al, 2002; Kindler, 2002; Lutz et al, 2002; Schilsky et al, 2002;
Pizzolato and Saltz, 2003; Schneider et al, 2003).
The current multicentre randomised phase II study was started
to investigate the feasibility and activity of the combination with
GEM plus CI 5-FU vs GEM alone in patients with APC. The
rationale of the combination of 5-FU with CI and GEM is to
prolong thymidylate synthetase inhibition, increasing the chance
of pharmacodynamic with GEM and to reduce toxicity with respect
to 5-FU bolus.
MATERIALS AND METHODS
Patient eligibility
The following inclusion criteria were mandatory to the study:
histological or cytological diagnosis of APC (locally advanced or
metastatic) with bidimensionally measurable disease. Patients were
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snot amenable to surgery or radiotherapy. Karnofsky performance
status (KPS) was 50 or greater, age between 18 and 75 years, no
prior chemotherapy, no central nervous system metastases, life
expectancy of at least 3 months, adequate haematological
(neutrophil count 41500dl
 1; platelet count 4100000dl
 1), renal
(serum creatinine o1.5 the upper limit of normal (ULN) value)
and hepatic (alkaline phosphatase o3 ULN value and bilirubin
o1.5 ULN value) functions. The protocol was approved by the
Ethical Committee and written informed consent was obtained
from all patients.
Treatment plan
Patients were centrally randomised by the central office of the
Italian Oncology Group for Clinical Research (GOIRC) to receive:
GEM alone (arm A) or in combination with CI 5-FU (arm B). GEM
was administered in both arms as a 30-min intravenous (i.v.)
infusion at the dose of 1000mgm
 2 once per week for 7 weeks,
followed by 2 weeks of rest. Thereafter, GEM was administered
once weekly for 3 consecutive weeks out of every 4 weeks. In arm
B, GEM was combined with CI 5-FU 200mgm
 2day
 1 i.v. for 6
weeks in the first cycle, followed by a week of rest and then for 3
weeks every 4 weeks. All patients were treated on outpatient basis.
Pretreatment evaluation and assessment of efficacy
At screening, all patients were evaluated with physical examina-
tion, complete blood count with leucocyte differential count,
serum creatinine, bilirubin, transaminase, and alkaline phospha-
tase, serum tumour marker (CEA and Ca 19-9) levels, ECG and
computed tomography (CT) scan of chest, abdomen and pelvis of
all tumour sites. During the study, patients were monitored before
each cycle for medical history, physical evaluation, clinical benefit,
serum chemistry and tumour markers, and evaluated for toxicity.
The RR (WHO) were assessed every 2 months or earlier if clinically
indicated. If a response was documented, treatment continued
until progression. Clinical evaluation of response was not used.
Pleural effusion, ascites and hepatomegaly were not used for
response assessment. In the case of grade 2 nonhaematological
toxicity or greater, patients received symptomatic therapy and 5-
FU therapy was stopped until the toxicity ceased and the dose was
reduced in the next cycle as follows: in the case of grade 2
stomatitis, diarrhoea or HFS, dose reduction was about 25% of
planned dose; in the case of grade 3 stomatitis, diarrhoea or HFS,
dose reduction of 5-FU was 50%; and in the case of grade 4
stomatitis, diarrhoea or HFS, 5-FU and GEM therapy was
discontinued. In the case of grade 2 haematological toxicity,
GEM dose was reduced by 25%; in the case of grade 3, dose
reduction was 50%; patientsdiscontinued from therapy when
treatment was associated with grade 4 neutropenia and infection.
Patients before each cycle received a diary for evaluation of quality
of life (QoL), according to Subjective Chemotherapy Impact (SCI)
questionnaire (Tamburini et al, 1991). The questionnaire allowed
us to assess the duration of physical and psychological discomfort
of patients during the treatment. The questionnaire consisted of
two items: (1) how many disturbed days did you have during the
treatment?; (2) how many days do you want to cancel during the
treatment? The questionnaire was answered before each cycle.
Statistical considerations
Primary end points of this study were RR. Secondary objectives
were to assess the OS, safety and tolerability of the regimens.
Overall survival was calculated from the first day of treatment until
the date of death. Patients alive at the end of study were censored
at last observation visit. For progression-free survival (PFS), the
last date PFS was the date of progression or death (if dead without
progression). Patients not experiencing progression or death were
censored at last observation visit. Progression-free survival and OS
were described according to the Kaplan–Meier method. Descrip-
tive statistics formed the primary basis of analysis for the data
collected in this study. The study was not powered for a formal
comparison of efficacy outcome measures, and these were not
performed. For each arm, a Simon’s optimal two-stage design was
chosen. According to this approach, the expected sample size is
minimised for the first stage if the regimen has low activity. It was
considered that the minimum RR had to be at least 10% and
combination would had been investigated further if it showed an
RR of 25% or more. Alpha and beta errors were fixed at 5 and 20%,
respectively. According to these assumptions, 18 patients per arm
had to be recruited in the first step if at least two responses were
observed, then a further 25 patients would have been enrolled, up
to a total of 43 patients per arm. A minimum of eight responses
was defined in order to claim activity.
RESULTS
Patient demographics
After 30 months of accrual, 94 patients were enrolled into this trial
and their characteristics are listed in Table 1. Three patients were
ineligible due to nonpathologic diagnosis of APC (n¼1),
synchronous second primary tumour (n¼1) and nonmeasurable
disease: pleural effusion (n¼1). The two arms of treatment were
well balanced for prognostic factors. The median age was 63 years
(range: 34–75 years). The KPS was X80 in 62 patients (68%) and
o80 in 29 patients (32%). In the GEM arm, 35 patients (73%) had
metastatic disease and 29 patients (67%) in the combination. In all,
48 patients (53%) had primary pancreatic tumour plus metastases
in the liver.
Table 1 Patient characteristics
GEM GEM+CI 5-FU
Characteristics No. (%) No. (%)
Enrolled 49 45
Evaluable 48 98 43 96
Median age (years) (range) 64 (34–75) 62 (44–75)
Gender
Male 23 48 27 63
Female 25 52 16 37
PS (Karnofsky)
X80 33 69 29 67
o80 15 31 14 33
Previous surgery
Yes 21 44 17 40
No 27 56 26 60
Site of disease
Pancreas alone 13 27 14 33
Pancreas+liver 28 58 20 47
Pancreas+nodes 6 13 6 14
Others 1 1 3 7
Disease at presentation
Locally advanced 13 27 14 33
Metastatic disease 35 73 29 67
GEM¼gemcitabine; CI¼continuous infusion; 5-FU¼5-fluorouracil; PS¼perfor-
mance status.
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sToxicity
A total of 253 cycles of chemotherapy were administered and the
median number of cycles was 2 (range: 1–6). In all, 90 patients in
both arms were evaluable for toxicity. The data toxicity of four
patients were missing. The most common side effects are shown in
Table 2. Both chemotherapy regimens were well tolerated. The
principal differences between the two regimens were grade 1 and 2
mucositis (arm A/B: 14 vs 29%) and diarrhoea (4 vs 20%). One
patient in the combination arm had grade 4 thrombocytopenia.
There were no treatment-related deaths.
Tumour response, PFS and survival
In total, 91 patients were evaluable for response: 48 (98%) and 43
(96%) patients in arms A and B, respectively. Two RR were
obtained in the first stage of study according to statistical
considerations. The OR rate was 9.9%, with a total of nine partial
responses (Table 3). There were no complete responses observed
in this study. In the patients treated with GEM alone, the overall
RR was 8% (95% confidence interval, 0.5–16%), while in the
combination arm, it was 11% (95% confidence interval, 2–22%).
The median duration of response was 34 weeks for GEM and 26
weeks for CI 5-FUþGEM. The median PFS was 14 weeks (range:
2–65 weeks) in the GEM arm alone and 18 weeks (range: 4–51
weeks) in the combination arm. Treatment with CI 5-FU plus GEM
obtained a median OS of 31 weeks and 30 weeks in GEM alone
(Figure 1). In all, 18% (arm A) and 20% (arm B) of patients
survived over 12 months. Patients were evaluated before each cycle
with QoL by SCI questionnaire. The analysis of the first cycles of
treatment showed no significant increase of mean disturbed days
(6.3 vs 4.8) and mean of days that patients would like to cancel
during the treatment (4.2 vs 3.0) in the GEM alone and
recombination arm. In the second cycle, the mean of disturbed
days was 4.2 vs 3.0 and cancelled days 0.2 vs 1.2, respectively.
DISCUSSION
Despite an increasing understanding of biology, diagnostic
technology and introduction of new drugs, the OS of patients
with APC remains poor. Until recently, 5-FU was considered one of
the standard agents in the treatment of APC and improved
therapeutic index was obtained using CI schedule.
Single-agent GEM is the currently recommended first-line
treatment for APC with an RR of 10% (range 5.4–14.3%), median
survival of 4.5 months and 1-year survival of 15–18%.
In a phase III trial, which compared 5-FU bolus with GEM,
survival (18 vs 2% at 1 year) and clinical benefit response (24 and
4.4%) were improved in the GEM arm. In a compassionate trial of
3023 patients treated with GEM, Storniolo et al (1999) reported a
median survival of 5.1 months in chemo-naı ¨ve and 3.9 in
previously treated patients.
In vitro studies, in HT-29 colon cancer cells, revealed synergy
when 5-FU was administered prior to GEM but not with
concurrent administration (Shulz et al, 1998; Madajewicz et al,
2000). GEM depletes cellular deoxyuridine monophosphate
(dUMP) pools, thereby decreasing competition with 5FdUMP at
the target enzyme thymidylate synthase (TS). GEM may also
inhibit TS. Finally, 5-FU metabolites may inhibit deoxycytidine
monophosphate deaminase, an enzyme responsible for the
inactivation of GEM monophosphate (Heinemann, 2002; GEM-
based combination treatment of pancreatic cancer). Preclinical
data do not evaluate the different methods of 5-FU administration
such as protracted CI therapy vs bolus therapy. 5-FU bolus have
reported disappointing results with a median survival of less than 5
months. More prolonged infusion schedules are associated with a
median OS time of 6–8 months
The combination of GEM and 5-FU have been used in a great
variety of schedules: 5-FU bolus, CI, standard-dose 5-FU or
protracted (24–48h) infusion of high-dose 5-FU given either at
weekly or biweekly intervals (Castellano et al, 2000; Louvet et al,
2001; Maurel et al, 2001).
Six studies, including 164 patients with APC, have evaluated CI
5-FU (200–250mgm
 2day
 1) in combination with GEM in APC
Table 2 Grade of adverse effects by treatment group
GEM, N¼49 GEM+CI 5-FU, N¼41
Grade (WHO)
Type of toxicity 1+2 3 4 1+2 3 4
Hematological
WBC 28 (57%) 1 (2%) — 17 (41%) 1 (2%) —
Haemoglobin 24 (49%) 3 (6%) — 14 (34%) 3 (7%) —
Platelets 7 (14%) — — 8 (20%) — 1 (2%)
Nonhaematological
Nausea/vomiting 21 (43%) — — 13 (32%) 1 (2%) —
Mucositis 7 (14%) — — 12 (29%) 2 (5%) —
Diarrhoea 2 (4%) — — 8 (20%) — —
Asthenia 20 (41%) 1 (2%) — 13 (32%) 1 (2%) —
Fever 9 (18%) 1 (2%) — 7 (17%) 2 (5%) —
GEM¼gemcitabine; CI¼continuous infusion; 5-FU¼5-fluorouracil.
Table 3 Objective response rate, duration of response, PFS and survival
data
Variable GEM, n (%) GEM+CI 5-FU, n (%)
Evaluable patients 48 43
CR — —
PR 4 (8%) 5 (11%)
(95% confidence interval) (0.5–16%) (2–22%)
SD 14 (29%) 12 (28%)
PR+SD 18 (37%) 17 (39%)
PD 30 (63%) 26 (61%)
Median duration response (range) 34 weeks (25–101) 26 weeks (16–46)
Median PFS (range) 14 weeks (2–65) 18 weeks (4–51)
Median OS (range) 31 weeks (1–101) 30 weeks (1–101)
PFS¼progression free survival; CR¼complete response; PR¼partial response;
SD¼stable disease; PD¼progression disease.
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s(Hidalgo et al, 1999; Anchisi et al, 2000; Shulman et al, 2000;
Alabiso et al, 2001; Rauch et al, 2001; Reni et al, 2001). Response
rate was between 13 and 51%, and OS between 5.3 and 10.3
months. Clinical benefit was only determined in three trials with
an RR of 31, 45 and 78% (Hidalgo et al, 1999; Alabiso et al, 2001;
Reni et al, 2001). Kurtz et al (2000), using GEM plus CI 5-FU,
reported an RR of 10 and 42% of stable disease (SD) with a median
survival of 4 months. GEM plus CI 5-FU was well tolerated and
major toxicities were principally mucositis, nausea/vomiting and
leukopenia. The toxicities of CI 5-FU and GEM do not overlap,
they can be used in combination at full doses, as demonstrated by
Hidalgo et al (1999). Recent data from studies comparing GEM
with or without 5-FU suggest that 5-FU bolus administration may
be of little or no benefit.
Berlin et al in a randomised trial of 327 patients used GEM alone
weekly for 3 weeks out of every 4 weeks or GEM followed by 5-FU
weekly on the same schedule (Berlin et al, 2002). The combination
arm did not improve the median OS (6.7 vs 5.4 months) compared
with GEM alone. The RR were in the range of 5.6 and 6.9% and PFS
2.2 months compared with 3.4 months for the combination. This
study did not demonstrate a synergistic activity of this combina-
tion with respect to GEM alone. This trial demonstrated that GEM
plus 5-FU is a tolerable regimen. Although toxicities were more
common on the GEM plus 5-FU arm, there was no significant
difference between the two arms. The most common grade 3 and 4
side effects were leukopenia, thrombocytopenia and diarrhoea.
Other trials using 5-FU bolus plus GEM reported a median
response of 14% (range 3.7–20%) and a median survival of 6.4
months (range 4.4–7.5 months) (Gutzler et al, 1999; Castellano
et al, 2000).
Our research group investigated a combination regimen of GEM
plus CI 5-FU vs GEM alone in a randomised phase II trial in APC.
The results do not suggest a better activity of combination over
GEM alone. The overall RR for all patients treated was 8% in GEM
alone and 11% in the combination arm. The evaluation of tumour
areas in pancreatic cancer is difficult, even with newer imaging
techniques, because of a vigorous desmoplastic reaction, including
inflammation and fibrosis within and around the tumour. In the
locally advanced pancreatic cancer, we used CT scan to parameter
the lesion with two perpendicular diameters, possibly excluding
desmoplastic reaction even if there were possible difficulties in
accuracy. In this trial, we did not obtain any objective response in
the primary tumour. Finally, median TTP and OS are similar in
both arms.
Historical comparisons between clinical trial are hazardous
because there is considerable variability between study population,
schedule and methodology of response evaluation, although with
these considerations in mind the median survival for GEM alone,
on GOIRC trial, was better than the principal studies with GEM
alone (7 vs 5.7 months). The RR and OS in trials with GEM plus 5-
FU bolus ranged from 3.7 to 20% and 5–10 months vs 13–25%
and 4–7 months with GEM plus CI 5-FU, respectively.
The incidence of gastrointestinal grade 3 and 4 toxicities was low
in both arms. Haematological toxicity was principally grades 1 and
2; only one patient (2%) developed severe thrombocytopenia.
Clinical benefit response, as introduced by Burris, was not
measured prospectively in this study. In this trial, patients with
disease confined to the pancreas alone (33% in the combination
arm and 27% in GEM alone) did not receive radiotherapy.
Although the more recent studies suggest a reasonable survival
time with CTþRT, the results are not convincingly better than
chemotherapy alone. Thus, it follows that it is not clear whether
CTþRT confers any survival advantage when compared with CT
alone (Neoptolemos et al, 2003). The patients were evaluated for
QoL by SCI questionnaire and there were no statistical differences
between the two arms, although only a small number of patients
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Figure 1 Survival curves estimated by the Kaplan–Meier method: Y-axis, probability of survival; X-axis, weeks.
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sreceived an evaluation for QoL after second cycles due to
progression of disease.
In conclusion, treatment of APC remains a challenge. This trial
demonstrated that the addition of CI 5-FU to GEM does not show
sufficient activity in order to be further tested in phase III trials.
Other trials with several different schedules or modulations
of 5-FU do not improve the outcome of pancreatic cancer. A
future goal could be represented by the introduction of targeted
therapies to improve disease control without significant added
toxicity.
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